Gemcitabine , ≥99% , 95058-81-4

CAS NO.：95058-81-4

Empirical Formula: C9H11F2N3O4

Molecular Weight: 263.2

MDL number: MFCD00869720

EINECS: 619-100-6

PRODUCT Properties

• Melting point: 168,64 C
• alpha: 365 +425.36°; D +71.51°
• Boiling point: 482.7±55.0 °C(Predicted)
• Density: 1.84±0.1 g/cm3(Predicted)
• storage temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• solubility: Methanol (Slightly), Water (Slightly, Heated)
• form: Solid
• pka: 11.65±0.70(Predicted)
• color: White to Off-White

Description and Uses

Gemcitabine is an anticancer nucleoside analog that inhibits the growth of HL-60 promyelocytic leukemia cells with an LC₅₀ value of 40 nM. It inhibits the growth of MX-1 mammary, CX-1, HC-1, GC3, and VRC5 colon, LX-1, Calu-6, and NCI-H460 lung, and HS766T, PaCa-2, PANC-1, and BxPC-3 pancreatic cancer tumors in mouse xenograft models (45-93% inhibition). Gemcitabine is a prodrug that is metabolized to a diphosphate and triphosphate form in cells. The triphosphate form is incorporated into DNA which induces masked chain termination and cell death. By specifically inhibiting growth arrest and DNA damage inducible protein 45 a (Gadd45a), a key mediator of active DNA demethylation, gemcitabine, at concentrations ranging from 34 to 134 nM, inhibits repair-mediated DNA demethylation in a methylation-sensitive reporter assay. Gemcitabine also has broad antiretroviral activity, decreasing MuLV cell infectivity, a murine AIDS model, in cell culture (EC₅₀ = ~1.5 nM) and inhibits the progression of murine AIDS in vivo at a dose of 1-2 mg/kg per day.

Gemcitabine is used for breast cancer treatment. First-line treatment for locally advanced pancreatic cancer.

Safety

• Symbol(GHS): GHS07
• Signal word: Danger
• Hazard statements: H312-H315-H319-H340-H361
• Precautionary statements: P280-P308+P313
• Hazard Codes: Xn,Xi
• Risk Statements: 21-36/38-46-62-63
• Safety Statements: 25-26-36/37-53
• HS Code: 29349990
• Toxicity: LD10 i.v. in rats: 200 mg/m2 (Abbruzzese)